UNSPSC 51312807: Alimemazine or trimeprazine

This classification denotes a sedative and hypnotic with the molecular formula C18H22N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76H78MJJ52, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl- but generally known as alimemazine, which bears US NIH Compound Identifier 5574. Alimemazine most often comes in base, s-dioxide, and tartrate forms. European Medicines Agency schedules Alimemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05328MIG.

UNSPSC 51312807 Alimemazine or trimeprazine is a Commodity code representing pharmaceutical products that state and local governments purchase through health and human services agencies, county health departments, and cooperative purchasing alliances. Based on recent solicitations, the code captures purchases of prescription pharmaceuticals and related drug products distributed through state and local health systems, community health initiatives, and government employee health benefit programs. State and local issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The scope of work encompasses procurement of generic multi-source pharmaceuticals and over-the-counter products for distribution through authorized pharmaceutical wholesalers, with vendors required to maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA).

Activity under the code shows geographic spread across the Southeast, Texas, and Upper Midwest. Recent representative opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating state and local facilities through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. MMCAP's contract term runs two years for new responders with optional extensions, effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent combined on fixed pricing, compliance with administrative data formats, EDI capability, and administrative fee structure.